Focused On-demand Library for Patatin-like phospholipase domain-containing protein 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Neuropathy target esterase

Alternative UPACC:

Q8IY17; A6NGQ0; B4DFB9; B7Z7T2; F5H5K9; J3KQS3; O60859; Q86W58; Q9UG58


Patatin-like phospholipase domain-containing protein 6, also known as Neuropathy target esterase, plays a crucial role in lipid metabolism by deacylating phosphatidylcholine to generate glycerophosphocholine. This enzymatic activity is pivotal for maintaining cellular lipid balance and is involved in the hydrolysis of several membrane-associated lipids.

Therapeutic significance:

The protein is implicated in several neurodegenerative disorders, including Spastic paraplegia 39, Boucher-Neuhauser syndrome, Laurence-Moon syndrome, and Oliver-McFarlane syndrome. These associations highlight its potential as a target for therapeutic intervention in these conditions, underscoring the importance of understanding its biological functions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.